Abstract
Measurement of strength and durability of SARS-COV-2 antibody response is important to understand the waning dynamics of immune response to both vaccines and infection. The study aimed to evaluate the level of IgG antibodies against SARS-CoV-2 and their persistence in recovered, naïve and vaccinated individuals. We randomly investigate Anti-spike RBD IgG antibody responses in 10,000 individuals, both following infection with SARS-CoV-2 and immunization with SARS-COV-2 adenoviral-vector and killed vaccines. Overall, antibody titres in recovered vaccinated individuals and naïve vaccinee persists beyond 20 weeks. The mean levels of anti-spike IgG antibodies were higher in vaccinated participants with prior COVID-19 infections than in individuals without prior infection. Decline for IgG antibodies were faster in vaccinated individuals without previous COVID-19 infection compared to those with previous COVID-19 infection. Vaccination with adenoviral–vector vaccines generates higher antibody titers than for killed virus vaccine. Slightly over half of asymptomatic unvaccinated individuals develops antibody response. Previous COVID-19 infection elicited robust and sustained levels of SARS-CoV-2 antibodies in vaccinated individuals. A single dose of the vaccine is likely to provide greater protection against SARS-CoV-2 infection in individuals with prior SARS-CoV-2 infection, than in SARS-CoV-2-naive individuals. This study also underlines that asymptomatic infection equally generates antibodies as symptomatic infection. Those vaccinated with inactivated vaccine may require more frequent boosters than those vaccinated with an adenoviral vaccine. These findings are important for formulating public health vaccination strategies during COVID-19 pandemic.
Importance Measurement of strength and durability of SARS-COV-2 antibody response is important to understand the waning dynamics of immune response to both vaccines and infection. We randomly surveyed 10,000 people for SARS-COV-2 antibodies. One vaccine dose with prior infection generated stronger immune response than two vaccine doses. Overall, antibody titres in recovered vaccinated individuals and naïve vaccinee persists beyond 20 weeks. Vaccination with adenoviral–vector vaccines generates higher antibody titers than for killed virus vaccine slightly over half of asymptomatic unvaccinated individuals develops antibody response. This study emphasise on the benefit of vaccination in inducing strong immune response. These findings are important for formulating public health vaccination strategies during COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Ministry of Health Libya.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by "The Bioethics Committee at the Biotechnology Research Center in Tripoli, Libya (Ref No. approved the study BEC-BTRC 8-2020).”
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
